Key result
Ventricular fibrillation therapy assurance (VFTA) enabled successful resuscitation by promptly delivering shocks after initial shock failure in low-amplitude VF.
Why the study?
Implantable cardioverter-defibrillator undersensing may delay therapy in ventricular fibrillation with low-amplitude signals.
Does Ventricular Fibrillation Therapy Assurance (VFTA) prevent misclassification and treatment delay of ventricular fibrillation with low-amplitude signals in patients with implantable cardioverter-defibrillators?
Does Ventricular Fibrillation Therapy Assurance (VFTA) prevent misclassification and treatment delay of ventricular fibrillation with low-amplitude signals in patients with implantable cardioverter-defibrillators?
Ventricular fibrillation therapy assurance (VFTA) can correct VF misclassification caused by low-amplitude signals, preventing life-threatening treatment delays in ICD patients.
Implantable cardioverter-defibrillator undersensing may delay therapy in ventricular fibrillation with low-amplitude signals. Ventricular fibrillation therapy assurance (VFTA) detected persistent VF after initial shock failure, enabling timely shock delivery and successful resuscitation. VFTA may help optimize device programming by preventing misclassification and treatment delay in life-threatening arrhythmias.
No takes yet. Share an insight, caveat, or question.
MATSUMOTO et al. (2026) studied this question. Ventricular fibrillation therapy assurance (VFTA) enabled successful resuscitation by promptly delivering shocks after initial shock failure in low-amplitude VF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: